<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03140657</url>
  </required_header>
  <id_info>
    <org_study_id>TabrizUMS-Rheumatology-003</org_study_id>
    <nct_id>NCT03140657</nct_id>
  </id_info>
  <brief_title>The Effects of Nanocurcumin on Serum miRNA and Th17 Cells Development Factors in Ankylosing Spondylitis Patients</brief_title>
  <official_title>The Effects of Oral Nanocurcumin on Expression Levels of microRNA and Th17 Cells Development Factors in Ankylosing Spondylitis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tabriz University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tabriz University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ankylosing spondylitis is a chronic autoimmune disease in which T cells associated with the
      disorder. The disease often affects the spine and hip bones. Inflammation involved in the
      area of the sacrum - Sacroiliac hip joints, pelvis, spinal lumbar, thoracic and cervical.
      Curcumin is a polyphenol. It is an active component of turmeric which is a perennial plant.
      Curcumin binding with a range of protein and the have ability to inhibit the activity of
      various kinases. Curcumin has a combination of activities such as antioxidant,
      anti-proliferation, anti-invasive, and can used in the treatment of Alzheimer's, Parkinson's,
      Multiple sclerosis, Cardiovascular disease, Bacterial diseases and Arthritis and ankylosing
      spondylitis. This increases the solubility of curcumin in nanomicelles spherical water to
      more than 100 thousand times, which significantly enhances the absorption of curcumin. A
      group of circulating miRNA in plasma is found to be the change they can be involved in
      inflammation or inhibit it. MiRNA expression profiles in blood and serum samples taken from
      patients with ankylosing spondylitis review that is miRNA-326 also affects cells of the
      immune system may be involved in disease ankylosing spondylitis. MiRNA-326 induces
      differentiation of Th17 cells via specific transcription factors, such as the RoRγt. MiRNA326
      increased the expression of transcription factor RoRγt and Th17 cell differentiation TCD4 +
      cells resulting in the production of inflammatory cytokine IL17 increased inflammation and
      progression of inflammatory disease ankylosing spondylitis (AS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized double-blind placebo control clinical trial conducted on two
      groups for 4 months. Patients receive oral nanocurcumin (80 mg / day) as compared with
      placebo group. After sampling both groups and separating plasma, peripheral blood mononuclear
      cells isolated by using ficoll and fresh and cultured in the presence of PHA. PBMC is used to
      measure the levels of miRNA-326, IL-17 and RORγt expression. the frequency of Th17 cells in
      peripheral blood will be examined by flowcytometry. To check the amount of the cytokine IL-17
      in cultured cells supernatant is used ELISA technique.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 29, 2017</start_date>
  <completion_date type="Anticipated">June 7, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 28, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessments of Ankylosing Spondylitis (ASAS) 20 Response</measure>
    <time_frame>at 4 months</time_frame>
    <description>Number of Subjects With a Reduction in Signs and Symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum mir-326 expression</measure>
    <time_frame>at 4 months</time_frame>
    <description>qPCR method (miRNA-326 induces differentiation of Th17 cells and increase inflammation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum IL-17 levels</measure>
    <time_frame>at 4 months</time_frame>
    <description>Elisa method (Th17 cells produce inflammatory cytokine, IL17, and increase inflammation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum RORγt expression</measure>
    <time_frame>at 4 months</time_frame>
    <description>qPCR method (RoRγt, a transcription factor, induce Th17 cell differentiation and increase inflammation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-17 expression</measure>
    <time_frame>at 4 months</time_frame>
    <description>qPCR method (Th17 cells produce inflammatory cytokine, IL17, and increase inflammation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Th17 cells frequency</measure>
    <time_frame>at 4 months</time_frame>
    <description>Flowcytometry (Th17 cells produce inflammatory cytokine, IL17, and increase inflammation).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Ankylosing Spondylitis</condition>
  <arm_group>
    <arm_group_label>Nanocurcumin Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nanocurcumin capsules (the formulation of curcumin nanoparticles, Exirnanosina). Subjects randomized to Nanocurcumin Arm will receive 80 mg/day for 4 month.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects randomized to Placebo Arm will receive placebo in the form of capsules for 4 month</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nanocurcumin</intervention_name>
    <description>Nanocurcumin capsules (the formulation of curcumin nanoparticles, Exirnanosina). Subjects randomized to Nanocurcumin Arm will receive 80 mg/day for 4 month</description>
    <arm_group_label>Nanocurcumin Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects randomized to Placebo Arm will receive placebo in the form of capsules for 4 month</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willingness to cooperate

          -  Aged 28 to 51 years

          -  The diagnosis of ankylosing spondylitis by rheumatologist

          -  Patients with a BASDAI &gt; 4 as having active disease.

          -  Disease duration 5-8 years

        Exclusion Criteria:

          -  Nutritional supplements and antioxidant alpha-lipoic acid a month before the study.

          -  Pregnancy and lactation

          -  History of diabetes and other chronic diseases

          -  History of other autoimmune diseases

          -  Occurrence of relapses during the study period

          -  Acceptance rate of less than 70% of supplements

          -  Unwillingness to continue to cooperate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mehdi Yousefi, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>SCARM institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mehrzad Hajaliloo Bonab, Rheumatologist</last_name>
    <role>Study Director</role>
    <affiliation>Tabriz University of Medical Sciences, Tabriz, Iran</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mehdi Yousefi, Ph.D</last_name>
    <phone>0912 670 3953</phone>
    <email>Yousefime@tbzmed.ac.ir</email>
  </overall_contact>
  <location>
    <facility>
      <name>Connective Tissue Diseases Research Center</name>
      <address>
        <city>Tabriz</city>
        <zip>0413</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanam Dolati, Ph.D</last_name>
      <phone>0914 402 5684</phone>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <reference>
    <citation>Wang C, Liao Q, Hu Y, Zhong D. T lymphocyte subset imbalances in patients contribute to ankylosing spondylitis. Exp Ther Med. 2015 Jan;9(1):250-256. Epub 2014 Nov 4.</citation>
    <PMID>25452811</PMID>
  </reference>
  <reference>
    <citation>Jethwa H, Bowness P. The interleukin (IL)-23/IL-17 axis in ankylosing spondylitis: new advances and potentials for treatment. Clin Exp Immunol. 2016 Jan;183(1):30-6. doi: 10.1111/cei.12670. Epub 2015 Sep 30. Review.</citation>
    <PMID>26080615</PMID>
  </reference>
  <reference>
    <citation>Wang X, Lin Z, Wei Q, Jiang Y, Gu J. Expression of IL-23 and IL-17 and effect of IL-23 on IL-17 production in ankylosing spondylitis. Rheumatol Int. 2009 Sep;29(11):1343-7. doi: 10.1007/s00296-009-0883-x. Epub 2009 Feb 27.</citation>
    <PMID>19247658</PMID>
  </reference>
  <reference>
    <citation>Rao TS, Basu N, Siddiqui HH. Anti-inflammatory activity of curcumin analogues. Indian J Med Res. 1982 Apr;75:574-8.</citation>
    <PMID>7118227</PMID>
  </reference>
  <reference>
    <citation>Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J. 2013 Jan;15(1):195-218. doi: 10.1208/s12248-012-9432-8. Epub 2012 Nov 10. Review.</citation>
    <PMID>23143785</PMID>
  </reference>
  <reference>
    <citation>Lv Q, Li Q, Zhang P, Jiang Y, Wang X, Wei Q, Cao S, Liao Z, Lin Z, Pan Y, Huang J, Li T, Jin O, Wu Y, Gu J. Disorders of MicroRNAs in Peripheral Blood Mononuclear Cells: As Novel Biomarkers of Ankylosing Spondylitis and Provocative Therapeutic Targets. Biomed Res Int. 2015;2015:504208. doi: 10.1155/2015/504208. Epub 2015 Jul 26.</citation>
    <PMID>26273623</PMID>
  </reference>
  <reference>
    <citation>Du C, Liu C, Kang J, Zhao G, Ye Z, Huang S, Li Z, Wu Z, Pei G. MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nat Immunol. 2009 Dec;10(12):1252-9. doi: 10.1038/ni.1798. Epub 2009 Oct 18. Erratum in: Nat Immunol. 2010 Jun;11(6):543.</citation>
    <PMID>19838199</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2017</study_first_submitted>
  <study_first_submitted_qc>May 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2017</study_first_posted>
  <last_update_submitted>January 28, 2018</last_update_submitted>
  <last_update_submitted_qc>January 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ankylosing spondylitis, Nanocurcumin, MicroRNA, Th17 cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

